Wednesday, July 14, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
Register Free: https://www.biopharminternational.com/bp/novel
Event Overview:
More than two-thirds of biotherapeutics are glycosylated proteins, which includes the therapeutically important category of monoclonal antibodies. The development and manufacturing of these potentially life-changing treatments, however, carries a high risk of failure and is technically challenging and expensive. Glycosylation is a critical product quality attribute that impacts on the efficacy and safety of glycosylated biotherapeutics and, therefore, must be characterized and monitored throughout product development and manufacturing processes.
Key Learning Objectives:
Who Should Attend:
Speakers
Victoria Smith PhD
Principal Scientist
CPI Biologics
Lewis Wharram
Analytical Scientist
CPI Biologics
Register Free: https://www.biopharminternational.com/bp/novel